Published in:
21-06-2022 | Multiple Sclerosis | Original Article
The alterations of cerebrospinal fluid TNF-alpha and TGF-beta2 levels in early relapsing–remitting multiple sclerosis
Published in: Immunologic Research | Issue 5/2022
Login to get accessAbstract
Aim of the study
This study aimed to analyze serum and cerebrospinal fluid (CSF) concentrations of proinflammatory and anti-inflammatory cytokines produced by T regulatory (Treg) cells in early RRMS according to the 2017 McDonald criteria.
Clinical rationale for the study
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating disease of the central nervous system (CNS) with the cytokine network playing an important role. However, there is a continual lack of data regarding the immunopathogenesis of early RRMS, especially according to the 2017 McDonald criteria.
Materials and methods
The study groups included early RRMS patients during relapse (n = 18), remission (n = 14), and the control group. The MS diagnosis was established according to the 2017 McDonald criteria. Patients were studied up to 1 year after diagnosis was made. A quantitative test kit based on ELISA was used for cytokine measurement in the serum and CSF. Comparative and correlation analyses between the levels of TNF-α, TGF-β2, IgG index, and relapse duration were performed.
Results
Significantly higher CSF concentrations of TNF-α in both RRMS–relapse and RRMS–remission groups were found compared to the controls (p < 0.01). The CSF levels of TGF-β2 in the RRMS–relapse group were significantly lower in comparison to the control group (p = 0.01).
Conclusions and clinical implications
An inappropriate inflammatory response seems to occur in early RRMS and includes the production of TNF-α and a decrease in TGF-β2 release suggesting a significant Treg cells role. Further studies on the topic may contribute to developing new disease-modifying drugs and biochemical markers of the disorder.